Iribarren Carlos, Chandra Malini, Molloi Sabee, Sam Danny, Sanchez Gabriela, Bidgoli Fatemeh Azamian, Cho Hyo-Min, Ding Huanjun, Lo Joan C
Kaiser Permanente Division of Research, Oakland, California.
Department of Radiological Sciences, University of California Irvine School of Medicine, Irvine, California.
J Endocr Soc. 2019 Nov 27;4(2):bvz026. doi: 10.1210/jendso/bvz026. eCollection 2020 Feb 1.
The association between bone mineral density (BMD) and breast arterial calcification (BAC) remains poorly understood and controversial.
The objective of this article is to examine the association between BMD and BAC in a large cohort of postmenopausal women undergoing routine mammography.
A cross-sectional analysis of baseline data from a multiethnic cohort was performed.
The setting for this analysis is an integrated health care delivery system in Northern California in the United States.
A total of 1273 women age 60 to 79 years (mean age, 67 years) were recruited within 12 months of screening mammography.
A BAC score (mg) was obtained from digital mammograms using a novel densitometry method. BAC presence was defined as a BAC score greater than 0 mg, and severe BAC as a BAC score greater than 20 mg.
Overall, 53% of women had osteopenia and 21% had osteoporosis. The prevalence of BAC greater than 0 mg was 29%, 30%, and 29% among women with normal BMD, osteopenia, and osteoporosis, respectively ( = 0.98). The prevalence of BAC greater than 20 mg was 5%, 3%, and 5% among women with normal BMD, osteopenia and osteoporosis, respectively ( = .65). The odds ratios (ORs) of BAC greater than 0 mg vs BAC = 0 mg after multivariable adjustment were 1.09 (95% CI, 0.81-1.48; = .54) for osteopenia and 0.99 (95% CI, 0.69-1.48; = .98) for osteoporosis. The adjusted ORs for BAC greater than 20 mg vs BAC 20 mg or less were 1.03 (95% CI, 0.52-2.01; = .93) for osteopenia and 1.89 (95 CI, 0.81-4.47; = .14) for osteoporosis.
Our findings do not support an association of either osteopenia or osteoporosis with BAC presence or severity among postmenopausal women.
骨矿物质密度(BMD)与乳腺动脉钙化(BAC)之间的关联仍未得到充分理解且存在争议。
本文旨在研究接受常规乳腺钼靶检查的大量绝经后女性中BMD与BAC之间的关联。
对一个多民族队列的基线数据进行横断面分析。
该分析的地点是美国北加利福尼亚的一个综合医疗保健系统。
在乳腺钼靶筛查的12个月内,共招募了1273名年龄在60至79岁(平均年龄67岁)的女性。
使用一种新型密度测定法从数字化乳腺钼靶片中获得BAC评分(毫克)。BAC的存在定义为BAC评分大于0毫克,严重BAC定义为BAC评分大于20毫克。
总体而言,53%的女性患有骨质减少,有21%患有骨质疏松症。在BMD正常、骨质减少和骨质疏松的女性中,BAC大于0毫克的患病率分别为百分之29、百分之30和百分之29(P = 0.98)。在BMD正常、骨质减少和骨质疏松的女性中,BAC大于20毫克的患病率分别为5%、3%和5%(P = 0.65)。多变量调整后,骨质减少组BAC大于0毫克与BAC = 0毫克相比的比值比(OR)为为1.09(95%置信区间,0.81 - 1.48;P = 0.54),骨质疏松组为0.99(95%置信区间,0.69 - 1.48;P = 0.98)。骨质减少组BAC大于20毫克与BAC小于或等于20毫克相比的调整后OR为1.03(95%置信区间,0.52 - 2.01;P = 0.93),骨质疏松组为1.89(95%置信区间,0.81 - 4.47;P = 0.14)。
我们的研究结果不支持绝经后女性中骨质减少或骨质疏松与BAC的存在或严重程度之间存在关联。